Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3502-3508

  Ryberg, Marianne ^a   Nielsen, Dorte ^a   Skovsgaard, Torben ^a   Hansen, Jes ^a   Jensen, Benny Vittrup ^a   Dombernowsky, Per ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; VINDESINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MORTALITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031734394     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3502     Document Type: Article

References (31)

1. Tormey DC: Adriamycin (NSC-123 127) in breast cancer: An overview of studies. Cancer Chemother Rep 6:319-327, 1975
2. Decker DA, Ahmann DL, Bisel HF, et al: Complete responders to chemotherapy in metastatic breast cancer: Characterisation and analysis. JAMA 242:2075-2079, 1979
3. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1970
4. Praga C, Beretta G, Vigo PL, et al: Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 63:827-834, 1979
5. Casazza AM, Di Marco A, Bertazzoli C, et al: Antitumor activity, toxicity, and pharmacological properties of 4′-epi-adriamycin, in Siegenthaler W, Luethy R (eds): Current Chemotherapy. Washington, DC, American Society for Microbiology, 1978, pp 1257-1260
6. Ritchie JL, Singer JW, Thorning D, et al: Anthracycline outcomes assessed by radionuclide ejection fraction. Cancer 46:1109-1116, 1980
7. Sorensen B, Bastholt L, Mirza MR, et al: The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: A phase I study in metastatic breast cancer. Cancer Chemother Pharmacol 34:439-443, 1994
8. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
9. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989
10. Chlebowski RT, Paroly WS, Pugh RP, et al: Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47-51, 1980
11. Goldin A, Venditti JM, Geran R: The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumours: A review. Invest New Drugs 3:3-21, 1985
12. Cersosimo RJ, Hong WK: Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an Adriamycin analogue. J Clin Oncol 4:425-439, 1986
13. Jain KK, Casper ES, Geller NL, et al: A prospective randomised comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
14. Brambilla C, Rossi A, Bonfante V, et al: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70:261-266, 1986
15. Hortobagyi GN, Yap HY, Kau SK, et al: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12:57-62, 1989
16. Perez DJ, Harvey VJ, Robison BA, et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152, 1991
17. Nielsen D, Dombernowsky P, Skovsgaard T, et al: Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol 1:275-280, 1990
18. Nielsen D, Larsen SK, Hansen OP, et al: Epirubicin (E) or epirubicin and cisplatin (P) as first line treatment in advanced breast cancer. Ann Oncol 1:24, 1990 (suppl)
19. Plosker GL, Faulds D: Epirubicin: Review of its pharmacodynamic and pharmacokinetics, and therapeutic use in cancer chemotherapy. Drugs 45:888-856, 1993
20. Nielsen D, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990
21. Criteria Committee of the New York Heart Association: Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis (ed 6). London, United Kingdom, Churchill, 1964
22. Buyse ME, Staquet MJ, Sylvester RJ: Cancer Clinical Trials Methods and Practice. Oxford, United Kingdom, Oxford, University Press, 1984
23. Praga C, Trave F, Petroccione A: Anthracycline-Induced Cardiotoxicity and Its Relevance in Cancer Treatment. Clinical Measurement in Drug Evaluation. London, United Kingdom, Wolfe Medical Duplications, 1991, pp 131-142
24. Torti FM, Bristow MR, Lum BL, et al: Cardiotoxicity of epirubicin and doxorubicin. Assessment by endomyocardial biopsy. Cancer Res 46:3722-3727, 1986
25. Dardir MD, Ferrans VJ, Mikhael SY, et al: Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 7:947-948, 1989
26. Neri B, Pacini P, Bartalucci S, et al: Epirubicin high-dose therapy in advanced breast cancer: Preliminary clinical data. Int J Clin Pharmacol Ther Toxicol 27:388-391, 1989
27. Billingham ME, Bristow MR, Glatstein E, et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17-23, 1977
28. Jensen BV, Nielsen SL, Skovsgaard T: Treatment with angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347:297-299, 1996
29. Jensen BV, Nielsen SL, Skovsgaard T: Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347:1485, 1996
30. Haq MM, Legha SS, Choksi J, et al: Doxorubicin-induced congestive heart failures in adults. Cancer 56:1361-1365, 1985
31. Moreb JS, and Oblon D: Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 70:2637-2641, 1992